Abstract:Pruritus is a sensation that leads to the desire to scratch; its origin is unknown in 8% to 15% of affected patients. The prevalence of chronic pruritus of unknown origin (CPUO) in individuals with generalised pruritus ranges from 3.6% to 44.5%, with highest prevalence among the elderly. When the origin of pruritus is known, its management may be straightforward if an effective treatment for the causal disease is available. Treatment of CPUO is particularly difficult due to its unknown pathophysiology. To assess the effects of interventions for CPUO in adults and children. We searched the following up to July 2019: Cochrane Skin Group Specialised Register, CENTRAL, MEDLINE, Embase, and trials registries. We checked the reference lists of included studies for additional references to relevant trials. We sought to include randomised controlled trials and quasi‐randomised controlled trials that assessed interventions for CPUO, as defined in category VI ('Other pruritus of undetermined origin, or chronic pruritus of unknown origin') of the International Forum for the Study of Itch (IFSI) classification, in children and adults. Eligible interventions were non‐pharmacological or topical or systemic pharmacological interventions, and eligible comparators were another active treatment, placebo, sham procedures, or no treatment or equivalent (e.g. waiting list). We used standard methodological procedures expected by Cochrane. Our primary outcomes were 'Patient‐ or parent‐reported pruritus intensity' and 'Adverse events'. Our secondary outcomes were 'Health‐related quality of life', 'Sleep disturbances', 'Depression', and 'Patient satisfaction'. We used GRADE to assess the certainty of evidence. We found there was an absence of evidence for the main interventions of interest: emollient creams, cooling lotions, topical corticosteroids, topical antidepressants, systemic antihistamines, systemic antidepressants, systemic anticonvulsants, and phototherapy. We included one study with 257 randomised (253 analysed) participants, aged 18 to 65 years; 60.6% were female. This study investigated the safety and efficacy of three different doses of oral serlopitant (5 mg, 1 mg, and 0.25 mg, once daily for six weeks) compared to placebo for severe chronic pruritus; 25 US centres participated (clinical research centres and universities). All outcomes were measured at the end of treatment (six weeks from baseline), except adverse events, which were monitored throughout. A pharmaceutical company funded this study. Fifty‐five per cent of participants suffered from CPUO, and approximately 45% presented a dermatological diagnosis (atopic dermatitis/eczema 37.3%, psoriasis 6.7%, acne 3.6%, among other diagnoses). We unsuccessfully attempted to retrieve outcome data from study authors for the subgroup of participants with CPUO. Participants had pruritus for six weeks or longer. Total study duration was 10 weeks. Participants who received serlopitant 5 mg may have a greater rate of relief of patient‐reported pruritus intensity as measured by the visual analogue scale (VAS; a reduction in VAS score indicates improvement) compared to placebo (126 participants, risk ratio (RR) 2.06, 95% confidence interval (CI) 1.27 to 3.35; low‐certainty evidence). We are uncertain of the effects of serlopitant 5 mg compared to placebo on the following outcomes due to very low‐certainty evidence: adverse events (127 participants; RR 1.48, 95% CI 0.87 to 2.50); health‐related quality of life (as measured by the Dermatology Life Quality Index (DLQI); a higher score indicates greater impairment; 127 participants; mean difference (MD) ‐4.20, 95% CI ‐11.68 to 3.28); and sleep disturbances (people with insomnia measured by the Pittsburgh Sleep Symptom Questionnaire‐Insomnia (PSSQ‐I), a dichotomous measure; 128 participants; RR 0.49, 95% CI 0.24 to 1.01). Participants who received serlopitant 1 mg may have a greater rate of relief of patient‐reported pruritus intensity as measured by VAS compared to placebo; however, the 95% CI indicates that there may also be little to no difference between groups (126 participants; RR 1.50, 95% CI 0.89 to 2.54; low‐certainty evidence). We are uncertain of the effects of serlopitant 1 mg compared to placebo on the following outcomes due to very low‐certainty evidence: adverse events (128 participants; RR 1.45, 95% CI 0.86 to 2.47); health‐related quality of life (DLQI; 128 participants; MD ‐6.90, 95% CI ‐14.38 to 0.58); and sleep disturbances (PSSQ‐I; 128 participants; RR 0.38, 95% CI 0.17 to 0.84). Participants who received serlopitant 0.25 mg may have a greater rate of relief of patient‐reported pruritus intensity as measured by VAS compared to placebo; however, the 95% CI indicates that there may also be little to no difference between groups (127 participants; RR 1.66, 95% CI 1.00 to 2.77; low‐certainty evidence). We are uncertain of the effects of serlopitant 0.25 mg -Abstract Truncated-

International study on prevalence of itch: examining the role of itch as a major global public health problem

Prevalence and Clinical Characteristics of Pruritus in Patients with Psoriasis

Chronic pruritus in multiple sclerosis and clinical correlates

Characteristics of pruritus in various clinical variants of psoriasis: Final report of the binational, multicentre, cross-sectional study

Lifetime prevalence and associated factors of itch with skin conditions: Atopic dermatitis, psoriasis and dry skin in individuals aged over 50

Severity, impact on quality of life and mental health burden of pruritus in prurigo nodularis: a cross-sectional study of a diverse patient cohort

Dermatological patients with itch report more stress, stigmatization experience, anxiety and depression compared to patients without itch: Results from a European multi‐centre study

Characteristics of Pruritus in Various Clinical Variants of Psoriasis: Results of the Multinational, Multicenter, Cross-Sectional Study

Prevalence and potential risk factors of chronic pruritus among community middle-aged and older population in Beijing, China

Pruritus and prurigo: a significant advancement on diagnosis, classification, pathogenesis and treatment

Self-reported generalised pruritus among community-dwelling older adults in Malaysia

Association Between Pruritus and Fibromyalgia: Results of a Population-Based, Cross-Sectional Study

Prevalence of scratching during examination among patients with scabies and among patients with other pruritic dermatoses

Evaluation of the Itchy Patient

Phenotyping peripheral neuropathies with and without pruritus: a cross-sectional multicenter study

Interventions for chronic pruritus of unknown origin.

122 Itchy Burns: Debilitating Effects of Pruritus on Daily Activity in Burn Follow-Up Care

Psychodermatology of Chronic Pruritus: An Overview of the Link Between Itch and Distress

Psychopathology Associated with Chronic Pruritus: A Systematic Review

Chronic Pruritus in the Absence of Skin Disease: Pathophysiology, Diagnosis and Treatment

Clinical characteristics of itch in cutaneous lupus erythematosus: A prospective, multicenter, multinational, cross-sectional study